vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and STARZ ENTERTAINMENT CORP (STRZ). Click either name above to swap in a different company.
STARZ ENTERTAINMENT CORP is the larger business by last-quarter revenue ($320.9M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -16.4%, a 15.7% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -7.5%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-31.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -40.6%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Starz Entertainment Corp., formerly known as Lions Gate Entertainment Corporation, or simply Lionsgate, is a Canadian-American entertainment company currently headquartered in Santa Monica, California. Founded by Frank Giustra on July 10, 1997, it is/was domiciled and incorporated in Vancouver, British Columbia.
AVNS vs STRZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $320.9M |
| Net Profit | $-1.3M | $-52.6M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | -10.8% |
| Net Margin | -0.7% | -16.4% |
| Revenue YoY | 0.7% | -7.5% |
| Net Profit YoY | 99.7% | -71.9% |
| EPS (diluted) | $-0.02 | $-3.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | — | ||
| Q3 25 | $177.8M | $320.9M | ||
| Q2 25 | $175.0M | $319.7M | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | $970.5M | ||
| Q3 24 | $170.4M | $346.9M | ||
| Q2 24 | $171.7M | $347.6M | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-52.6M | ||
| Q2 25 | $-76.8M | $-42.5M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | $-21.9M | ||
| Q3 24 | $4.3M | $-30.6M | ||
| Q2 24 | $1.8M | $4.2M | ||
| Q1 24 | $-900.0K | — |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | -10.8% | ||
| Q2 25 | -42.6% | -8.4% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | 3.7% | ||
| Q3 24 | 7.0% | -4.9% | ||
| Q2 24 | 3.7% | 2.9% | ||
| Q1 24 | 2.4% | — |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -16.4% | ||
| Q2 25 | -43.9% | -13.3% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | -2.3% | ||
| Q3 24 | 2.5% | -8.8% | ||
| Q2 24 | 1.0% | 1.2% | ||
| Q1 24 | -0.5% | — |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | $-3.15 | ||
| Q2 25 | $-1.66 | $-2.54 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | $-0.09 | ||
| Q3 24 | $0.09 | $-1.83 | ||
| Q2 24 | $0.04 | $0.26 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $37.0M |
| Total DebtLower is stronger | $90.3M | $608.7M |
| Stockholders' EquityBook value | $778.2M | $663.2M |
| Total Assets | $1.1B | $2.0B |
| Debt / EquityLower = less leverage | 0.12× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | $37.0M | ||
| Q2 25 | $90.3M | $51.6M | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | $200.5M | ||
| Q3 24 | $89.0M | $229.6M | ||
| Q2 24 | $92.2M | $192.5M | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | $608.7M | ||
| Q2 25 | $95.7M | $611.7M | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $2.4B | ||
| Q3 24 | $152.6M | $2.1B | ||
| Q2 24 | $164.9M | $1.5B | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | — | ||
| Q3 25 | $778.0M | $663.2M | ||
| Q2 25 | $776.3M | $712.3M | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | $-168.3M | ||
| Q3 24 | $1.2B | $935.9M | ||
| Q2 24 | $1.2B | $973.1M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.0B | $2.1B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $7.2B | ||
| Q3 24 | $1.7B | $7.1B | ||
| Q2 24 | $1.7B | $7.2B | ||
| Q1 24 | $1.7B | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | 0.92× | ||
| Q2 25 | 0.12× | 0.86× | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | 2.24× | ||
| Q2 24 | 0.13× | 1.59× | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-26.1M |
| Free Cash FlowOCF − Capex | $21.3M | $-31.3M |
| FCF MarginFCF / Revenue | 11.8% | -9.8% |
| Capex IntensityCapex / Revenue | 3.8% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-317.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | $-26.1M | ||
| Q2 25 | $6.8M | $65.4M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $-335.3M | ||
| Q3 24 | $23.0M | $9.1M | ||
| Q2 24 | $27.8M | $-33.5M | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | $-31.3M | ||
| Q2 25 | $-4.2M | $58.5M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $-349.3M | ||
| Q3 24 | $20.0M | $4.4M | ||
| Q2 24 | $21.9M | $-38.4M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | -9.8% | ||
| Q2 25 | -2.4% | 18.3% | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | -36.0% | ||
| Q3 24 | 11.7% | 1.3% | ||
| Q2 24 | 12.8% | -11.0% | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | 1.6% | ||
| Q2 25 | 6.3% | 2.2% | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | 1.4% | ||
| Q3 24 | 1.8% | 1.4% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | -7.98× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
STRZ
| Over The Top Subscription Service OTT | $222.8M | 69% |
| Linear Subscription Service | $98.1M | 31% |
